trending Market Intelligence /marketintelligence/en/news-insights/trending/t-ptqn9qulo1nheo756zng2 content esgSubNav
In This List

Therapix Biosciences director resigns

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Therapix Biosciences director resigns

Mark Groussman has resigned as a director of Therapix Biosciences Ltd.

Groussman's resignation was not related to any disagreement with the board on any matter relating to the operations, policies or practices, according to Therapix.

Tel Aviv, Israel-based Therapix Biosciences is a specialty clinical-stage pharmaceutical company that develops drugs based on cannabinoid molecules.